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Abstract: One-hundred-and-twenty-eight recipients of 131 consecutive, 
non-matched cadaver renal allografts were treated with cyclosporine 
and steroids. They have been followed for 4 to 6 yr. Cumulative patient 
survival at I-yr was 92.2% and at 6yr it is 77.8%. Cumulative graft survival 
at I-yr was 79.4% and at 6 yr it is 50.0%. After the high-risk 1st yr, the 
rate of graft loss was even and similar to that reported after the 1st yr 
for grafts treated with azathioprine and steroids. This indicates that 
cyclosporine nephrotoxicity has not had an obvious adverse effect on 
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the survival of chronically functioning grafts. The results were better with 
primary grafting versus retransplantation, but were not significantly 
influenced by age, diabetes mellitus, or a delayed switch in patients from 
cyclosporine to azathioprine. We have concluded that cyclosporine-
steroid therapy is safe and effective for long-term use after cadaveric renal 
transplantation. 
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Cyclosporine is now in widespread use for the pre-
vention of rejection after cadaveric renal transplan-
tation. The drug was first used clinically by CaIne 
and associates (1, 2) who were able to achieve 
chronic graft function in many of their patients 
without any other agent. However, patient mor-
tality was high, significant nephrotoxicity was com-
mon, and 3 of their first 34 recipients developed 
lymphomas (1). 
We have recommended combined immunosup-
pressive therapy with cyclosporine and steroids (3, 
4). Although the drug combination has been safe 
and effective (5, 6), nagging doubts have remained 
about the long-term efficacy and safety of cyclo-
sporine. We present here results from our first 131 
consecutive cadaveric renal transplantations per-
formed from late 1979 through 1981. Follow-ups 
are available for 4 to 6 yr. 
Matarlal and mathods 
Case Material 
There were 128 patients in the trial of whom 93 
were given primary grafts. Second, third or fourth 
This study was supported by Research Project Grant No. 
AM-29961 from the National Institutes of Health, Bethesda, 
Maryland. 
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transplantations were carried out in 35 patients 
who had rejected grafts at earlier times under con-
ventional immunosuppression. Three of the 128 
patients in the trial, 2 from the primary group and 
1 from the retransplantation group, lost their grafts 
despite cyclosporine-steroid therapy and were re-
transplanted during the 1979-1981 period of case 
accrual. Thus, there was a total of 131 transplan-
tations done under cyclosporine-steroid therapy. 
The first 57 primary transplantations and 10 
retransplantations were done at the University of 
Colorado Health Sciences Center in Denver (5). 
The remainder were done at the University Health 
Center of Pittsburgh (4, 6). Deliberate blood trans-
fusion for recipient conditioning was not practiced 
in Colorado during these trials and was inconsi-
stently used in Pittsburgh. Consequently, only a 
minority of recipients had a history of transfusion 
(3-6). There were 86 males and 42 females, from 9 
to 63 yr old (mean 37.5 ± 11.9, S.D.). Eleven pa-
tients (8.5%) were juvenile onset diabetics. In 
nearly half the patients, the cause of end stage renal 
disease was not definitively known. 
Tissue matching 
Cytotoxic antidonor antibodies were avoided with 
conventional crossmatch techniques using current 
recipient sera. Otherwise, matching was random in 
most cases. In the Colorado series, HLA antigen 
mismatches at the A and B loci averaged 3.3 ± 1.3, 
S.D. and only 10 of the 66 patients had as few as 
2 mismatches (5). In the Pittsburgh series, HLA A 
or B matches averaged 0.79±0.9, S.D. from pri-
mary graft recipients and 1.46 ± 1.3, S.D. for pa-
tients undergoing retransplantation (6). Since DR 
typing data were not available at the time of tran~­
plantation, DR matching was random and Ulll-
formly poor. 
Immunosuppression 
The first 22 patients in the Colorado series had 
pretreatment, from a few days up to 3 months with 
cyclosporine, thoracic duct drainage, or lympha-
pheresis (3, 5). Pretreatment was not used there-
after. In the first recipients, prednisone was with-
held postoperatively until there were clinical signs 
of rejection. It became obvious that rejection oc-
curred in most of the patients unless steroids were 
used from the beginning and therefore steroids 
were used prophylactically in all subsequent pa-
tients (4). 
Several hours before operation, 17.5 mg/kg of 
cyclosporine were given orally. If tolerated, this 
daily dose was continued for 2 months postoperati-
vely before being reduced. Earlier reductions were 
made in the event of toxic side-effects (4). Later 
in the course, the cyclosporine doses were almost 
always weaned so that the average daily dose by 
the end of l-yr was 5 to 6 mg/kg (5, 6). Blood 
plasma levels of cyclosporine were not regularly 
moni tored in 1979-1981. 
In adults, a 5-d burst of steroids was given, be-
ginning with 200 mg of methylprednisolone or pre-
dnisone on the day of operation. The dose was 
reduced by 40 mg/d until a daily maintenance dose 
of 20 mg was reached (4). Further reductions in 
the dose of prednisone were dictated by the clinical 
course. Rejections were treated with a 1 g bolus of 
methylprednisolone followed by a repeat of the 5-
d cycle of high-dose prednisone. In children the 
steroid doses were adjusted downward in accord-
ance with size and weight. 
Statistics 
Follow-up was available for all 131 grafts and 128 
patients 48 to 72 months after transplantation. 
There were no exclusions. Actuarial patient and 
graft survivals were calculated by the life table 
method (7, 8). In transplantation, most patient 
deaths bear some potential relationship to therapy. 
Therefore, all graft losses, including those which 
Cyclosporine-steroids in cadaver renal graft 
Table 1. Principal cause of 27 deaths 
Before 1 year After 1 year Total 
Infection 7 (5) 6 (3) 13 (8) 
Myocardial infarction 1 (1) 4 (2) 5 (3) 
Aortic aneurysm 0 3 (3) 3 (3) 
Sudden death during coronary an-
giography 1 (1) 0 1 (1) 
Hemorrhage after coronary reva-
scularization 1 (1) 0 1 (1) 
Pulmonary embolus after hip sur-
gery 1 (1) 0 1 (1) 
Suicide 0 1 (1) 1 (1) 
Auto accident 0 1 (1) 1 (;1) 
Unknown 0 1 (0) 1 (0) 
Total 10 (8) 17 (11) 27 (19) 
( ) indicates grafts functioning at time of death. 
were functioning at the time of death, were counted 
as failures. 
Results 
Patient survival 
Patient survival for the entire series is summarized 
in Fig. 1. Twenty-seven (21.1 %) of the patients 
have died, including 10 (7.8%) deaths within 1 yr 
of operation. Three (2.3%) of these fatalities were 
from myocardial infarction, sudden death during 
coronary angiography, or hemorrhage during cor-
onary artery reconstruction within 30 d after trans-
plantation and these were counted as operative 
deaths (Table 1). Four other patients died of myo-
cardial infarctions 16, 23, 52 and 54 months after 
transplantation. Ruptured or dissecting abdominal 
aneurysms accounted for 3 late deaths. 
Infections were responsible for l3 deaths (Table 
1) including 2 from pulmonary nocardiasis after 8 
and 10 months, 1 from a perforated colonic diver-
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Fig. 1. Actuarial (life table) survival for 128 patients and 131 
non-matched cadaveric renal transplants performed between 
December, 1979 and December, 1981 with cyc1osporine-predni-
sone therapy. 
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ticulum after 25 months, 1 from disseminated hi-
stoplasmosis after 27 months, and 2 from hepatitis 
after 26 and 45 months. Nineteen (70.4%) of the 
27 deaths occurred while there was still adequate 
graft function (Table 1). 
There was no statistically significant difference 
in survival between recipients of primary grafts and 
retransplants (Fig. 2A). Seventeen patients were 
taken off cyclosporine therapy 6 to 53 months after 
transplantation, usually because of suspected 
nephrotoxicity. These 17 recipients survived at the 
same rate as recipients kept on cyclosporine. Four-
teen are still alive. Of the 3 who died, 2 had 
functioning grafts after 25 and 26 months. Colonic 
diverticulitis and perforation and a pulmonary em-
bolus after hip surgery accounted for 2 deaths. The 
3rd patient, who lost his primary graft, died of a 
ruptured abdominal aneurysm 16 months after he 
was retransplanted. 
There were II diabetic patients in the series 
(8.6%). Their percentage survival was the same as 
nondiabetics. Three diabetic patients were lost with 
functioning grafts including 1 at 37 months in an 
automobile accident, the 2nd at 45 months from 
peripheral vascular disease, septicemia and myo-
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Fig. 3. Actuarial patient survival (A) and graft survival (B) for 
24 recipients over 50 yr of age and 104 recipients under 50 yr 
at transplantation. 
cardial infarction, and the 3rd at 52 months from 
myocardial infarction. Eight diabetic patients 
(72.7%) remain alive. 
The 24 patients in this series over the age of 50 
yr at the time of transplantation survived at the 
same rate as younger patients during the 4 to 6 yr 
of follow-up (Fig. 3A). 
Graft survival 
Overall, 79.4% of the 131 grafts functioned for at 
least 1 yr (Fig. 1). At 4 yr, 76 (58.0%) were still 
functioning (Fig. 1). After 49 to 72 months, 69 
(52.7%) are functioning with a mean serum creatini-
neofl58.9 ± 0.9, S.D. J..lmol/ml (range 70.6 to 441.5). 
Three patients with functioning grafts have a serum 
creatinine of greater than 350 J..lmol/ml and evidence 
of chronic rejection. At present, these are the only 
grafts at probable high risk of imminent loss. 
Graft survival for primary grafts was significant-
ly better than after retransplantation. The differ-
ence was evident at 6 months (p<O.Ol) and has 
remained significant out to 60 months (Fig. 2B). 
After the 1st yr, the annual rate of loss has been 
approximately the same for primary grafts as for 
Table 2. Causes of 62 graft losses 
Primary Re-graft All 
Reiection 22 16 38 
Patient death 16 3 19 
Oxalosis 1 2 
Hemolytic uremic syndrome 0 1 
Technical accident 1 1 2 
Total 40 22 62 
retransplants. After 4 to 6 yr, 53 (57.0%) of the 93 
primary grafts and 16 (42.1 %) of the 38 retrans-
plants are functioning. . 
The most frequent causes of graft loss were reJec-
tion and recipient death (Table 2)_ One primary 
graft was lost to recurrent oxalosis at 11 months. 
The patient was retransplanted but lost th.e 2n? 
graft to oxalosis within 2 mo~thsK q~e patIent IS 
still alive on dialysis. Hemolytic uremic syndrome 
destroyed 1 graft following a pregnancy 33 months 
after transplantaion. The 2 technical losses were 
from ureteral necrosis and renal vein thrombosis. 
Graft survival in the 17 patients who were with-
drawn from cyclosporine was not significantly dif-
ferent from that in patients who were kept on the 
drug. Sixteen of these patients were converted to 
azathioprine 20.8 ± 11.0, S.D. months (range 6. t? 
45 months) after transplantation. The 17th recIpI-
ent withdrew himself from cyclosporine at 53 
months and has a perfectly functioning graft at 65 
months on 15 mg/d of prednisone. He has declined 
therapy with azathioprine. In addition to 2 
functioning grafts lost by patient death, 3 graf~s 
were lost to rejection in patients switched to azathi-
oprine after 6, 19 and 21 months. ~he 3 grafts 
failed 4, 46 and 4 months later, respectively. Twelve 
(70.6%) of the 17 grafts are still functioning after 
50 to 72 months. 
Graft survival has been the same for diabetics 
and non-diabetics. In addition to 3 grafts in dia-
betics lost by patient death, 1 graft was lost to a~ 
early renal vein thrombosis in a p~tient of O.-pOSI-
tive ABO blood type who was accidentally gIven a 
kidney from an A donor. Only 1 graft has been 
lost to rejection in a diabetic patient and that oc-
curred after 45 months. Seven (63.6%) of the grafts 
in diabetic patients are still functioning. 
Graft survival in patients over 50 yr of age at 
the time of transplantation has been the same as 
graft survival in younger patients (Fig. 3B). 
Current cyclosporine dose 
For the 57 patients still being treated with cyclospo-
rine, the mean daily dose is 4.3 ± 1.8, S.D. mg/kg. 
Cyclosporine-steroids in cadaver renal graft 
Daily dosage has remained fairly constant beyond 
2 yr after transplantation. 
Malignancy 
Two lymphomas diagnosed during life and treated 
with local resection and reduction of immunosup-
pression (9) have not recurred after 5! ~nd 66 
months. A third similar lesion was an InCIdental 
autopsy finding in a patient who died of pneumo-
nitis. Another patient has been living for more than 
4 yr in symbiosis with a dissemi~atedK Kaposi's 
sarcoma which waxes and wanes WIth adjustments 
in cyclosporine dose, which is presently 1 mg/kg/ 
d. Two carcinomas have been diagnosed in males 
with excellent graft function. One patient has wide-
spread metastases from an unknown primar~ 71 
months after transplantation. The other patient 
developed a lacrimal duct cancer 3 yr after trans-
plantation which was controlled with radiotherapy, 
and then comitted suicide when a separate oropha-
ryngeal carcinoma developed after 4 yr. 
Discussion 
Nephrotoxicity as the principal dose-limiting factor 
with cyclosporine administration has been recog-
nized since the first clinical trials with this drug (1). 
The strategy of adding steroids, azathioprine, or 
antilymphocyte globlulin (ALG) to reduced doses 
of cyclosporine has permitted good immunosup-
pression without excessive n~phrotoxicityK ~ow­
ever chronic interstitial fibroSIS has been descnbed 
in r~nal allografts (10) and in the kidneys of heart 
transplant recipients (11) long after transplantation. 
Determination of the possible adverse influence 
of chronic cyclosporine upon patient or renal graft 
100% 
;:w 
COLOAADO-P I TTSBUAGH ..J 80 
"" CYCLOSPOAINE SEAlES u UJ 
t.!l 60 
------
a 
d 
40 I ..J ~~----"" ~ 
> 
a: 
:::> 
UJ 
... UCLA KIONEY REGISTRY 
"-
AZATHIOPRINE SERIES "" a: 20 t.!l 
... 
Z 
UJ 
u 
a: 
UJ 
11. 
10 
0 12 24 36 48 60 72 
MONTHS 
Fig. 4. Actuarial survival (log scale) for 93 primary no?-
matched cadaveric renal transplants with cyclosponne-sterOld 
therapy compared with 11 861 cadaveric transplan.ts with con-
ventional immunosuppression from the UCLA kidney trans-
plant registry (13). 
47 
~----~-----------~~--K-------
_ .. ------_._---_. ---
Gordon et al. 
survival was the principal focus of this review of 
our earliest series of patients. The results were simi-
lar to those in a 3-yr follow-up study by CaIne & 
Wood (12) of European renal recipients. The pa-
tient mortality, which was 7.8% in the 1st yr, is 
projected to be about 22% at the end of 5 yr, a 
half decade mortality which is far lower than in 
pooled series from North America (13) or the 
southern region of the United States (14) for pa-
tients under azathioprine-steroid maintenance. The 
principal causes of death from infection and car-
diovascular complications have been the same as 
in the past but at a reduced rate. The hypertension 
which has been associated with cyclosporine (15) 
may have been an added risk factor in the 9 pa-
tients who died from cardiovascular complications, 
but there is no clear evidence for this. Six patients 
developed malignant tumors, but 3 were of the 
lymphoma variety associated with Epstein-Barr vi-
rus infections which have been shown to regress 
with discontinuance or reduction of immunosup-
pression (9). There were only 2 malignant epithelial 
tumors, an incidence greater than in a normal pop-
ulation averaging nearly 40 yr of age, but less than 
that recorded by Penn in renal transplant recipients 
under chronic immunosuppression (16). 
The chronic survival and stability of function 
of these largely unmatched cadaveric kidneys was 
encouraging. During the first years of treatment, 
little was known about how to best use cyclospori-
ne and routine pharmacologic monitoring of drug 
levels was not available. It is likely that many of 
these patients were treated at toxic levels for signifi-
cant periods of time. Despite evidence of cyclospo-
rine nephrotoxicity in many patients during the 1st 
yr, graft function has not significantly deteriorated 
during the subsequent 3 to 5 yr. Some patients with 
extreme elevations of BUN and creatinine at 1 yr 
have had stable and even improving function dur-
ing ensuing years. 
The fact that l-yr cadaver graft survival could 
be improved with cyc1osporine has been evident 
for some time. Now it can be stated that the rate 
of graft loss after 1 yr is no greater than that 
reported by Terasaki et al. (13) in nearly 12000 
North American recipients of primary cadaveric 
allografts under conventional immunosuppression 
(Fig. 4) and by McDonald et al. (14) in the region 
of the United States served by the Southeast Organ 
Procurement Foundation. The comparable rate of 
late graft loss under cyclosporine-steroid therapy 
is especially significant because conditions which 
can favorably influence survival curves, such as 
selection of patients on the basis of tissue matching, 
immunologic or medical low risk factors, or sys-
48 
tematic conditioning of patients by deliberate 
blood transfusion were not features of this trial. 
It was interesting that the rate of late graft loss 
in the 15 patients switched from cyc1osporine to 
azathioprine was less t han in the larger group 
maintained on cyclosporine. However, the number 
of cases was small and the differences were not 
significant. We do not suggest on the basis of this 
trial that late switchover from cyclosporine to az-
athioprine should be considered more commonly. 
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